Triple therapy in type 2 diabetes (T2DM): Benefits of insulin glargine (GLAR) over rosiglitazone (RSG) added to combination therapy of sulfonylurea plus metformin (SU plus MET) in insulin-naive patients

被引：0

|

作者：

Rosenstock, J

Sugimoto, D

Strange, P

Stewart, J

Soltes-Rak, E

Dailey, G

机构：

来源：

DIABETES | 2004年 / 53卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A145 / A145

页数：1

相关论文

共 50 条

[1] Triple therapy in Type 2 diabetes: benefits of insulin glargine over rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients
Rosenstock, J
Sugimoto, D
Strange, P
Stewart, J
Rak, ES
Dailey, G
[J]. DIABETOLOGIA, 2004, 47 : A57 - A57
[2] Triple therapy in type 2 diabetes - Insulin glargine or rosiglitazone added to combmiation therapy of sulfonylurea plus metformin in insulin-naive patients
Rosenstock, J
Sugimoto, D
Strange, P
Stewart, JA
Soltes-Rak, E
Dailey, G
[J]. DIABETES CARE, 2006, 29 (03) : 554 - 559
[3] Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients - Response to Hamid and Simmons
Rosenstock, Julio
[J]. DIABETES CARE, 2006, 29 (10) : 2332 - 2332
[4] Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients - Response to Rosenstock et al.
Hamid, Zulekha
Simmons, Debra L.
[J]. DIABETES CARE, 2006, 29 (10) : 2331 - 2331
[5] Insulin glargine (GLAR) improves health related quality of life (HRQOL) in patients with type 2 diabetes (T2DM) inadequately controlled on sulfonylurea plus metformin (SU plus MET)
Vinik, AI
Dailey, G
Zhang, Q
[J]. DIABETES, 2005, 54 : A142 - A142
[6] Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy
Hollander, Priscilla
Sugimoto, Danny
Vlajnic, Aleksandra
Kilo, Charles
[J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (08) : 1266 - 1271
[7] Insulin plus metformin for T2DM—are there benefits?
Clifford J. Bailey
[J]. Nature Reviews Endocrinology, 2012, 8 : 449 - 450
[8] Benefits of combination with rosiglitazone (RSG) and metformin (MET) over uptitration to maximal dose MET in previously drug-naive type 2 diabetes mellitus (T2DM) patients
Garber, A
Wooddell, MJ
Strow, LJ
Waterhouse, BR
Cobitz, AR
[J]. DIABETES, 2004, 53 : A475 - A475
[9] Rosiglitazone (RSG) added to metformin (MET) delays insulin initiation in type 2 diabetes patients
Koro, CE
Sahota, JE
Hulme, LR
Fedder, DO
[J]. DIABETES, 2004, 53 : A247 - A247
[10] Greater benefits of rosiglitazone (RSG) added to submaximal dose of metformin (MET) compared to maximizing metformin dose in type 2 diabetes mellitus (T2DM) patients
Rosenstock, J
Goldstein, BJ
Wooddell, MJ
Strow, LJ
Waterhouse, BR
Cobitz, AR
[J]. DIABETES, 2004, 53 : A144 - A145

← 1 2 3 4 5 →